Financial Performance - Revenue for the year ended December 31, 2025, reached RMB 644.6 million, representing a year-on-year increase of 20.7% compared to RMB 533.9 million in 2024[2]. - Gross profit for the same period was RMB 476.3 million, up 18.3% from RMB 402.7 million in 2024[2]. - Profit before tax surged to RMB 122.2 million, marking a 132.3% increase from RMB 52.6 million in the previous year[2]. - Net profit for the year was RMB 119.2 million, reflecting a 128.0% growth compared to RMB 52.3 million in 2024[2]. - Basic earnings per share increased to RMB 0.40 from RMB 0.17, reflecting strong profitability growth[12]. - The company reported a total comprehensive income of RMB 116,946,000 for the year, up from RMB 53,288,000 in 2024[14]. - The company reported a pre-tax profit of RMB 122.181 million for 2025, compared to RMB 52.601 million in 2024, marking a 132.4% increase[38]. - The group’s gross profit increased by approximately 18.3% from RMB 402.7 million for the year ending December 31, 2024, to approximately RMB 476.3 million for the year ending December 31, 2025, with a gross margin of about 73.9%, down from 75.4%[112]. Product Development and Regulatory Approvals - The company received regulatory approval for 11 new products during the reporting period, enhancing its product portfolio significantly[3]. - AcoArt Verbena® and AcoArt Canna® received regulatory approval, expanding the company's product offerings in the drug-coated balloon segment[5][6]. - The company has received registration approval for eleven new products during the reporting period, including six in vascular surgery and three in cardiology[68]. - The vascular surgery approvals include pressure-controlled thrombectomy extension tubes and peripheral high-pressure balloon dilatation catheters, among others[68]. - The company has received regulatory approvals for multiple products, including drug-coated technologies for SFA and PPA diseases, with CE marking in Europe and NMPA approval in China[70]. - The company has received regulatory approval for the AcoArt AVENS® high-pressure balloon for treating arteriovenous fistula stenosis in hemodialysis patients as of April 2023[92]. - The company anticipates obtaining regulatory approval for the lower limb rapamycin DCB by 2027, which has shown preliminary efficacy in animal models[81]. - The company has received regulatory approval for the peripheral hydrophilic coated guidewire in August 2025, with no significant adverse events reported since the approval date[84]. Market Expansion and Sales - The company has established a sales and marketing team covering over 3,000 hospitals in China and recorded active sales in 17 countries globally[4]. - The company aims to continue expanding its product registration globally and explore broader collaboration opportunities with Boston Scientific[9]. - The company plans to continue expanding its market presence, particularly in the domestic market, while focusing on innovation and new product development[28]. - The company has established active sales of its cooperative products in 17 countries globally as of the end of the reporting period[104]. - The company aims to strengthen its global market presence through strategic partnerships and marketing activities[136]. Research and Development - The company has a total of 653 employees as of December 31, 2025, with 145 in the R&D team, emphasizing its commitment to talent development[11]. - Total R&D expenses were RMB 269.563 million, up from RMB 258.726 million in 2024[34]. - The company has established a comprehensive talent development and training framework to support its business growth[11]. - The company is committed to obtaining necessary documentation and quality systems to support global commercialization of its products and services[153]. - The company plans to enhance its R&D capabilities through increased investment in technological innovation to maintain its leading position in the DCB market[106]. Financial Position and Resources - Current assets rose to RMB 1,336,885,000, compared to RMB 1,210,572,000 in 2024, indicating improved liquidity[15]. - Total equity increased to RMB 1,476,085,000 from RMB 1,349,816,000, reflecting the company's strong financial position[16]. - The total available financial resources amounted to approximately RMB 948.0 million as of December 31, 2025, a 9.7% increase from RMB 864.2 million as of December 31, 2024, mainly due to cash generated from operating and financing activities[123]. - The total borrowings amounted to RMB 68.3 million as of December 31, 2025, compared to RMB 10.0 million as of December 31, 2024, leading to an increase in the debt-to-equity ratio from approximately 23.2% to 26.6%[124]. - The company has sufficient bank credit facilities to support its capital expenditures[134]. Strategic Partnerships - The strategic partnership with Boston Scientific has been extended through a new framework agreement, enhancing global commercialization efforts[8]. - The company has entered into a total cooperation agreement with BSG for the period from July 20, 2023, to December 31, 2025, focusing on collaborative efforts[148]. - Three R&D projects have been initiated under the R&D services agreement with BSG, focusing on joint product development and regulatory approval[66]. - The company is actively exploring opportunities to expand its product registration globally and seeks joint development opportunities with BSG[66]. Corporate Governance - The board of directors includes both executive and non-executive members, ensuring a diverse governance structure[152]. - The company will continue to review its corporate governance practices to ensure compliance and enhance shareholder value[140]. - The company has adopted a standard code of conduct for securities trading, confirming compliance by all directors during the reporting period[143].
先瑞达医疗(06669) - 2025 - 年度业绩